Newsroom
ProMedEx Reports 10% Increase in Net Profit in H1-26
By KlickAnalytics Data Insights | August 31, 2026 06:04PM ET
- Earnings per share for the period rose to SAR 6.95 in H1-26, compared to SAR 6.32 in the prior-year half
- Total revenues increased by 11.93% to SAR 212.71 million in H1-26 from SAR 190.04 million
ProMedEx, a leading medical company based in Riyadh, announced a significant 10% increase in net profit, reaching SAR 24.32 million in the first half (H1) of 2026 compared to SAR 22.11 million recorded in the same period of 2025. This growth was reflected in the rise of earnings per share to SAR 6.95, up from SAR 6.32 in the prior-year half, as disclosed in a recent bourse filing. The company's total revenues also saw a robust increase of 11.93% to SAR 212.71 million in H1-26 from SAR 190.04 million in the previous year.
The company attributed this positive financial performance primarily to the SAR 21.20 million growth in its Saudi Arabian operations, representing an 11.3% rise in domestic business. ProMedEx also saw an increase of SAR 8.88 million in gross profit, coupled with the absence of expected credit losses that had amounted to SAR 1.56 million in the previous year. Furthermore, financing costs decreased by SAR 0.33 million, contributing to the overall profitability.
In addition, ProMedEx noted an impressive 32.42% growth in total shareholders' equity, which reached SAR 174.52 million in H1-26, compared to SAR 131.80 million in the same period a year earlier. The company reported that certain comparative figures were reclassified for consistency, including a transfer of SAR 1.02 million from prepaid expenses to intangible assets, with no significant impact on previously reported net profit.
ProMedEx's strong financial results in the first half of 2026 showcase its resilience and solid business strategy, positioning the company for further growth and success in the medical industry.
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with